HBK Investments’s AbbVie ABBV Stock Holding History

HBK Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-42,500	Closed	-$6.51M	–	415
2022 Q2	$6.51M	Buy	+42,500	New	+$6.49M	0.04%	174
2021 Q2	–	Sell	-37,900	Closed	-$4.1M	–	822
2021 Q1	$4.1M	Buy	37,900 +28,600	+308%	+$3.06M	0.02%	315
2020 Q4	$996K	Sell	9,300 -95,000	-91%	-$9.13M	0.01%	495
2020 Q3	$9.14M	Hold	104,300	–	–	0.07%	122
2020 Q2	$10.2M	Buy	+104,300	New	+$9.18M	0.13%	88
2020 Q1	–	Sell	-70,800	Closed	-$6.27M	–	22
2019 Q4	$6.27M	Buy	+70,800	New	+$5.88M	0.06%	211
2019 Q3	–	Sell	-8,600	Closed	-$625K	–	616
2019 Q2	$625K	Sell	8,600 -19,200	-69%	-$1.51M	0.01%	475
2019 Q1	$2.24M	Buy	27,800 +14,100	+103%	+$1.15M	0.02%	483
2018 Q4	$1.26M	Sell	13,700 -11,900	-46%	-$1.05M	0.01%	615
2018 Q3	$2.42M	Buy	+25,600	New	+$2.43M	0.02%	473

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HBK Investments's ABBV Position: Q2 2022 in Review

HBK Investments sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,371 shares — an estimated $209K sold.

HBK Investments first reported a position in ABBV in Q4 2015 and held it in 14 quarters. The position peaked at $30.7M in Q2 2018. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

HBK Investments reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
HBK Investments sold 1,371 AbbVie shares in Q2 2022, an estimated $209K.
HBK Investments first reported a position in AbbVie in Q4 2015 and held it in 14 quarters.
HBK Investments's AbbVie position peaked at $30.7M in Q2 2018.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on HBK Investments's 13F filing for Q2 2022, filed 15 Aug 2022.